<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560725</url>
  </required_header>
  <id_info>
    <org_study_id>2020KT107</org_study_id>
    <nct_id>NCT04560725</nct_id>
  </id_info>
  <brief_title>PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer</brief_title>
  <official_title>PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and&#xD;
      evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially&#xD;
      those with recurrent or advanced PCa).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the most common malignancy of the male reproductive system.Prostate&#xD;
      specific membrane antigen is a highly specific prostatic epithelial cell membrane antigen,&#xD;
      which is highly expressed in solid tumors such as prostate cancer. More than 90% of prostate&#xD;
      cancer cells express PSMA, so PSMA can be used as an important imaging target for prostate&#xD;
      cancer.Positron emission tomography has the advantages of non-invasive, high resolution and&#xD;
      high sensitivity, etc. The PET tracer based on PSMA radiographic label is developing rapidly,&#xD;
      which is of great significance for the early diagnosis, prognosis and treatment of prostate&#xD;
      cancer.Used for radionuclide 68Ga has a half-life of PET imaging (T1/2 = 68 min) is&#xD;
      appropriate, prepared from 68Ge-68Ga generator, relatively low cost, coordination marking&#xD;
      method is simple, easy to realize automatic synthesis technology and advantages of medicine&#xD;
      preparation, so 68Ga- labeled PSMA targeted molecular probe in prostate cancer has been&#xD;
      widely applied in the diagnosis of disease.&#xD;
&#xD;
      [68Ga]P137 is a novel PSMA targeted molecular probe labeled with 68Ga. DOTA is used as a&#xD;
      bifunctional linker to coordinate with 68Ga3+. The labeling method is simple, the biological&#xD;
      stability is high, the tumor site has obvious radioactive enrichment, and the imaging effect&#xD;
      is superior.This project provides research on [68Ga]P137 PET/CT imaging for patients with&#xD;
      suspected PCa, and provides basis for early diagnosis of PCa, formulation of treatment plan&#xD;
      and efficacy evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>2 years</time_frame>
    <description>The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROC</measure>
    <time_frame>2 years</time_frame>
    <description>The curve of the relationship between sensitivity and specificity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>[68Ga] P137</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo [68Ga]P137 PET/CT scans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-Choline</intervention_name>
    <description>11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the [68Ga]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT</description>
    <arm_group_label>[68Ga] P137</arm_group_label>
    <other_name>11C-CH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men over 18 years of age need to undergo [68Ga]P137 PET/CT examination for suspected&#xD;
             prostate cancer.&#xD;
&#xD;
          -  The patients can fully understand and voluntarily participate in this experiment, and&#xD;
             sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant hepatic or renal dysfunction;&#xD;
&#xD;
          -  Patients with malignant tumors other than prostate cancer within 2 years;&#xD;
&#xD;
          -  Ready to pregnant;&#xD;
&#xD;
          -  The patient can not tolerate all clinical tests.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhi Yang, Professor</last_name>
    <phone>010-88196495</phone>
    <email>pekyz@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Zhu, Associate Professor</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teli Liu</last_name>
      <phone>010-88196196</phone>
      <email>liuteli123321@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanan Ren</last_name>
      <phone>18286135605</phone>
      <email>1913282072@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hua Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PSMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

